Recent Notice of Allowance is for Aclarion’s 24th issued US patent Propionic acid (PA) is a biomarker the literature suggests may be indicative of bacterial infection and pain in an ...

Inc trading halted, volatility trading pauseMaximize Your Portfolio with Data Driven Insights:Leverage the power of ...

Northwestern Medicine is a global leader in clinical trial research, including spine CLARITY is a randomized study designed to demonstrate Nociscan’s ability to improve surgical outcomes while ...

Inc trading resumesMaximize Your Portfolio with Data Driven Insights:Leverage the power of TipRanks' Smart Score, a ...

(RTTNews) - Aclarion, Inc. (ACON) announced on Tuesday the issuance of a new patent for the use of Magnetic Resonance Spectroscopy (MRS) to detect and measure propionic acid throughout the body.

Aclarion, Inc. (NASDAQ: ACON) shares cleared breakeven Tuesday, as the health-care technology company announced it has received a Notice of Allowance from the United States Patent and Trademark Office ...

CLARITY is a randomized study designed to demonstrate Nociscan’s ability to improve surgical outcomes while reducing costs for chronic low back pain Nociscan aims to become the gold standard in ...

BROOMFIELD, Colo. - Aclarion, Inc. (NASDAQ:ACON, ACONW), a healthcare technology company, announced today it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a ...